Prostate Cancer Approaches, Treatment Evolve In Asia Amid Wider Therapy Shifts
Executive Summary
While multiple new approaches and drugs are being developed for different stages of prostate cancer globally, many remain unavailable across Asia Pacific markets, despite a rising overall incidence of the disease. Two specialists recently shared with Scrip their views on treatment issues and optimum approaches in this fast-changing environment, and how they see the broader role of existing and new therapies developing given recent clinical results and practice.
You may also be interested in...
Clovis In Pole Position To Be First PARP For Prostate Cancer
Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.
How The Prostate Cancer Market Will Look Over Next Decade
As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.